The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Vinorelbine plus cisplatin versus gefitinib in resected non-small cell lung cancer haboring activating EGFR mutation (WJOG6410L).
Hirohito Tada
Honoraria - Kyowa Hakko Kirin
Koji Takeda
No relevant relationships to disclose
Kazuhiko Nakagawa
Honoraria - AstraZeneca; Kyowa Hakko Kirin
Isamu Okamoto
Honoraria - AstraZeneca; Kyowa Hakko Kirin
Tetsuya Mitsudomi
Consultant or Advisory Role - Kyowa Hakko Kirin
Honoraria - AstraZeneca
Yukito Ichinose
Honoraria - AstraZeneca; Kyowa Hakko Kirin
Kenji Sugio
Honoraria - AstraZeneca; Kyowa Hakko Kirin
Masahiro Tsuboi
Honoraria - AstraZeneca
Yoichi Nakanishi
Honoraria - AstraZeneca; Kyowa Hakko Kirin